Gagliardini, Roberta
 Distribuzione geografica
Continente #
NA - Nord America 1.371
EU - Europa 1.056
AS - Asia 648
SA - Sud America 136
Continente sconosciuto - Info sul continente non disponibili 34
AF - Africa 23
OC - Oceania 2
Totale 3.270
Nazione #
US - Stati Uniti d'America 1.322
SG - Singapore 310
DE - Germania 226
PL - Polonia 209
FR - Francia 167
SE - Svezia 149
CN - Cina 143
IT - Italia 113
BR - Brasile 105
VN - Vietnam 56
GB - Regno Unito 48
UA - Ucraina 47
IN - India 39
IE - Irlanda 30
CA - Canada 21
ID - Indonesia 19
RU - Federazione Russa 18
FI - Finlandia 17
BD - Bangladesh 14
HK - Hong Kong 13
AR - Argentina 12
JP - Giappone 12
TR - Turchia 11
MX - Messico 10
NL - Olanda 7
ZA - Sudafrica 7
JM - Giamaica 6
BE - Belgio 5
CO - Colombia 5
IR - Iran 5
LT - Lituania 4
SA - Arabia Saudita 4
TN - Tunisia 4
VE - Venezuela 4
CL - Cile 3
EC - Ecuador 3
MA - Marocco 3
PH - Filippine 3
AM - Armenia 2
AT - Austria 2
AU - Australia 2
CR - Costa Rica 2
DK - Danimarca 2
EG - Egitto 2
ES - Italia 2
EU - Europa 2
IQ - Iraq 2
KE - Kenya 2
MD - Moldavia 2
MY - Malesia 2
NI - Nicaragua 2
PA - Panama 2
AG - Antigua e Barbuda 1
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BB - Barbados 1
BO - Bolivia 1
CG - Congo 1
CH - Svizzera 1
EE - Estonia 1
ET - Etiopia 1
GH - Ghana 1
GR - Grecia 1
HN - Honduras 1
HR - Croazia 1
IL - Israele 1
KG - Kirghizistan 1
KR - Corea 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MM - Myanmar 1
MT - Malta 1
NP - Nepal 1
OM - Oman 1
PE - Perù 1
PK - Pakistan 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
SC - Seychelles 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 3.238
Città #
Kraków 199
Chandler 183
Singapore 154
Ashburn 127
San Jose 97
New York 64
Jacksonville 52
Beijing 31
Dublin 30
Redmond 30
Los Angeles 29
San Mateo 29
Milan 27
The Dalles 26
Houston 24
Ann Arbor 20
Dallas 20
Ho Chi Minh City 20
Lauterbourg 20
Jakarta 19
Nanjing 18
Boston 17
Dearborn 17
Council Bluffs 16
Hanoi 15
Wilmington 15
Nürnberg 14
Rome 14
Cattolica 13
Santa Clara 13
Hong Kong 12
Lawrence 12
Changsha 11
Frankfurt am Main 11
Lancaster 11
Tokyo 10
Woodbridge 10
Nanchang 9
North Bergen 9
Brooklyn 8
Buffalo 8
Fairfield 8
Roubaix 8
Seattle 8
Atlanta 7
Izmir 7
Montreal 7
Redwood City 7
São Paulo 7
Warsaw 7
Kunming 6
Manchester 6
Munich 6
Paris 6
Princeton 6
Pune 6
Bexley 5
Johannesburg 5
Marseille 5
Orem 5
Shenyang 5
Toronto 5
Verona 5
Washington 5
Amsterdam 4
Augusta 4
Brussels 4
Chennai 4
Falls Church 4
Hangzhou 4
Hebei 4
Kingston 4
Little Rock 4
Mexico City 4
Phoenix 4
San Francisco 4
Stockholm 4
Anápolis 3
Biên Hòa 3
Boardman 3
Calgary 3
Cambridge 3
Chicago 3
Clearwater 3
Des Moines 3
Edgewood 3
Elkhart 3
Guangzhou 3
Helsinki 3
Jinan 3
Leawood 3
London 3
Poplar 3
Port Townsend 3
Portsmouth 3
Queens 3
Turin 3
University Park 3
Andover 2
Ankara 2
Totale 1.725
Nome #
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 242
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 236
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 233
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 232
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 219
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 209
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 199
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 195
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 184
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 175
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 171
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 162
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 161
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 151
Liver fibrosis progression and clinical outcomes are intertwined: Role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCVcoinfected patients with detectable HCV-RNA A MASTER cohort study 148
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study 130
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 121
Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors 102
Totale 3.270
Categoria #
all - tutte 12.266
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.266


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022168 0 0 0 0 6 15 4 36 14 29 26 38
2022/2023426 66 69 29 68 28 55 7 50 44 1 8 1
2023/2024205 6 63 4 23 12 50 14 1 0 2 22 8
2024/2025360 3 14 21 11 40 7 8 29 73 25 70 59
2025/2026846 130 10 40 112 174 37 156 40 37 65 33 12
2026/2027248 24 30 37 142 15 0 0 0 0 0 0 0
Totale 3.270